Latest News
We help inventions grow!
Nov 30, 2023
IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023
Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio)...
Apr 25, 2023
The Prague.bio international conference will bring together the best of science and business in Prague.
The first edition of the Prague.bio international conference will offer a unique meeting of representatives from science and business who will exchange their experiences in the development of new drugs, diagnostics, medical technologies and other areas of biotechnology. The event is supported by the Czech government and will feature renowned experts from the world of BioTech.
Feb 7, 2023
New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper
The academic startup Sophomer today announced the signing of a licensing agreement to commercialize a technology that can replace the traditionally used bovine serum albumin (BSA) in immunoassays. The newly licensed technology has been developed in collaboration between the Institute of Macromolecular Chemistry of the CAS (IMC), Elisa Development and the bio-innovation center i&i Prague. The signing of the license agreement also officially accelerated the activities of the startup...
Feb 6, 2023
Czech liquid biopsy startup Elphogene comes under full control of one of the founders
Czech biotechnology start-up Elphogene who pioneered cancer monitoring through its liquid biopsy technology has announced a change in its shareholder structure. The new and sole owner is now Marek Minarik, one of the two original founders of the company. In the portfolio of the bio-innovation centre i&i Prague, Elphogene was one of the oldest startups. Now our mission is over.
Dec 23, 2022
We are looking for new Antonin Holy and new drugs and diagnostics that can have a global impact and success
"i&i Bio invests in technology transfer with a strong focus on healthcare. We look for unique technologies that come from Czech and foreign science. We always try to find something new and unique, something that could bring great benefit to patients and also to our investors," says Jaromír Zahrádka for Fintag.cz. The podcast is in the Czech language.
i&i Prague Highlights
Highlights from i&i Bio
We have moved the investment part of our business to our associated venture capital firm, i&i Biotech Fund I. Here you can find the most important news from (i&i Bio).
i&i Biotech Fund will invest up to EUR 340 000 into Czech startup Sophomer s.r.o.
The Czech academic startup Sophomer s.r.o. has announced an investment of up to EUR 340 000 from i&i Biotech Fund. The funding will be used for further technology development, team expansion and new laboratory space. Sophomer s.r.o. was established at the end of 2022 ...
The Advisory Committee of i&i Biotech Fund strengthened by renowned economist Daniel Münich
i&i Biotech Fund announces the launch of cooperation with Associate Professor Daniel Münich, who has joined the Fund's Advisory Committee. The renowned Czech economist will join the European Investment Fund's (EIF) delegate as a representative of the bio-innovation center, i&i Prague, ...
Experienced businessmen join forces with excellent science, invest EUR 2 million in the fund at the IOCB
Leading Czech businessmen have joined the support of the most promising scientific projects. Eight prominent entrepreneurs have contributed nearly €2 million to the i&i Biotech Fund (i&i Bio), an investment fund that specializes in finding and developing unique academic startups in the ...
i&i Bio invests more than €1 M in Enzyre to help to advance diagnostic technology platform for hemophilia patients
Enzyre, a company developing a breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million Series A funding led by new investor Oost NL, with participation from i&i Biotech Fund, Demcon Investment ...
